Vinge represents Altor Fund V in connection with its investment in H2 Green Steel. The investment has been carried out in connection with H2 Green Steel's series B round totalling approx. EUR 190 million. Investors participating in the capital raise included, in addition to Altor, inter alia AMF, GIC, Swedbank Robur Alternative Equity, FAM and IMAS Foundation.

H2 Green Steel was founded in 2020 with the ambition to accelerate the decarbonization of the steel industry, using green hydrogen. Steel, which is one of the world’s largest carbon dioxide emitters, is the company’s first business vertical. H2 Green Steel is headquartered in Stockholm, Sweden, with its first green steel plant under development in Boden, northern Sweden.

Vinge's team consisted mainly of Christina Kokko, Johan Larsson, Carl Fredrik Wachtmeister, Linus Adolfsson (M&A), Lisa Hörnqvist, Elis Allmark (Commercial Agreements), Johan Cederblad (Environment), Kristoffer Larsson (Real Estate), Julia Löfqvist (Compliance), Kamyar Najmi (Banking and Finance), Axel Lennartsson (IP), Ebba Svenburg (Employment), Sara Dahlros Sköld and Julia Hagelberg (project assistants).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025